In connection with the implementation of the project titled “Design and development of an innovative solution – a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes”, funded from the state budget by the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., requested to submit a bid for the purchase and delivery of a primary reference standard for Semaglutide.
Details of the price inquiry can be found in the attached document.